Impact Therapeutics Inc

Impact Therapeutics Inc: Impact Therapeutics is a privately held clinical-stage biopharmaceutical company and dedicates to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has assembled the most comprehensive DNA damage response (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline.
Senaparib is a novel agent targeting PARP (poly-ADP ribose polymerase) developed by Impact. Early clinical data showed that senaparib had the potential to be the best-in-class PARP inhibitor with better safety profile and wider therapeutic window. These enable senaparib more suitable for long-term therapies and combination therapies. Impact and Junshi Biosciences established a 50:50 joint venture that focuses on the development and commercialization of senaparib in China. The JV is currently conducting a Phase II pivotal study and a Phase III study of senaparib in ovarian cancer third-line treatment and first-line maintenance treatment in China. Impact alone is conducting a global study of Senaparib and temozolomide combination therapy in solid tumors and small cell lung cancer treatment.
IMP7068 is a novel Wee1 inhibitor discovered and developed by Impact Therapeutics, with worldwide intellectual property, part of in-house DDR franchise. Compared to other Wee1 inhibitor, IMP7068 has better selectivity, longer half-life, and higher drug exposure, all of which would potentially lead to superior therapeutic window in treating patients. Impact has received US IND clearance for IMP7068.
IMPACT also is developing multiple DDR agents including ATR, ATM, Chk1/2 and undisclosed novel synthetic lethality programs for the treatment of cancer, as well as hedgehog pathway inhibitor IMP5471, which is in preparation for China IND, as potential treatment for cancers and fibrosis diseases.
Sector/Industry:
Healthcare
Characteristics:
Based in...
Asia
Clinical Stage
Phase III
Disease Space
Oncology
Listing
Private
Website:
Address:
111 Xiangke Road
Building 3, Room 603
Pudong District, Shanghai, 200135
China

Company Participants at Fall Private Company Showcase 2021

  • Jun Bao, PhD, CEO

Upcoming Company Event Participation